Nymox Pharmaceutical Corporation
NYMXF
$0.1364
$0.026424.00%
OTC PK
| 09/30/2024 | 12/31/2023 | 09/30/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -59.77% | 390.47% | -40.07% | -40.07% | -47.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.60% | 387.66% | -31.53% | -31.53% | -38.06% |
| Operating Income | 35.60% | -387.66% | 31.53% | 31.53% | 38.06% |
| Income Before Tax | 30.89% | -296.64% | 30.52% | 30.52% | -182.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 30.89% | -296.64% | 30.52% | 30.52% | -182.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.89% | -296.64% | 30.52% | 30.52% | -182.84% |
| EBIT | 35.60% | -387.66% | 31.53% | 31.53% | 38.06% |
| EBITDA | 35.44% | -386.97% | 28.80% | 28.80% | 33.54% |
| EPS Basic | 31.25% | -288.59% | 31.29% | 31.29% | -182.43% |
| Normalized Basic EPS | 31.43% | -256.99% | 31.37% | 31.37% | -181.72% |
| EPS Diluted | 10.71% | -288.59% | 44.00% | 44.00% | -222.00% |
| Normalized Diluted EPS | 31.43% | -256.99% | 31.37% | 31.37% | -196.20% |
| Average Basic Shares Outstanding | 1.50% | 2.26% | 0.98% | 0.98% | 0.93% |
| Average Diluted Shares Outstanding | 1.50% | 2.26% | 0.98% | 0.98% | -13.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |